LGND - CIK 0000886163
The table below shows LIGAND PHARMACEUTICALS INC's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | $48.69M | -$25.45M | $18.73M | $33.95M | $52.01M | $10.75M |
| Capital expenditure | $228.00K | $214.00K | $105.00K | $2.41M | $4.88M | $3.40M |
| Investing cash flow | -$94.35M | $4.89M | -$3.77M | $10.55M | $113.88M | $65.11M |
| Dividends paid | - | - | - | - | - |
LIGAND PHARMACEUTICALS INC reported operating cash flow of $49.36M for fiscal year 2025. That is down 49.1% from $97.05M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from $60.73M (FY 2016) to $49.36M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | $0.00 |
| Financing cash flow | -$14.13M | -$4.75M | $12.18M | -$775.00K | -$170.42M | -$91.64M |